知镜 Cognispect · 医学文献与研究工作台

MRGPRX2 antagonist treatment prevents inflammation and disease in a mouse model of atopic dermatitis.

Wollam J, Solomon M, Villescaz C, Srinivasan S, Charlot B, Vest A, Napora J, Cavarlez C, Vasquez A, Dvorak L, Viswanath V.
The Journal of investigative dermatology · 2026-05-04 · PMID 42092534

文献摘要

The Mas-related G-protein-coupled receptor X2 is a promiscuous receptor expressed on mast cells that mediates IgE-independent mast cell activation and degranulation in response to a variety of diverse agonists and has been implicated in numerous inflammatory conditions, including atopic dermatitis (AD). We investigated whether the small-molecule Mas-related G-protein-coupled receptor X2 antagonist INCB000262 improves disease phenotype in the house dust mite + Staphylococcus aureus enterotoxin type B (HDM+SEB) mouse model of AD and further characterized mast cell-mediated aspects of disease. Mas-related G-protein-coupled receptor X2 knock-in mice were sensitized to HDM+SEB and orally dosed once daily with either vehicle or INCB000262 for 4 weeks, and efficacy and skin transcriptional changes were evaluated. INCB000262 attenuated HDM+SEB-induced AD in vivo, with improvements observed in skin thickness, transepidermal water loss, tissue weight, and overall clinical score. In addition, transcriptome changes induced by HDM+SEB exhibited a mast cell activation signature consistent with human AD lesional skin, which was attenuated by antagonist treatment. Overall, INCB000262, a Mas-related G-protein-coupled receptor X2 antagonist, attenuated HDM+SEB-induced AD disease phenotypes and mast cell-associated transcriptional changes, supporting further evaluation of INCB000262 as an oral treatment for AD and other mast cell-mediated diseases.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。